Lymphangitic carcinomatosis is a difficult to treat disease entity and usually portends a poor prognosis given the advanced state in which it is often diagnosed. Treatment is usually based on standard therapy of the primary malignancy, but in most cases, is palliative in nature. This case highlights the potential for PD-1 immunotherapy as both a rapid and durable treatment for lymphangitic carcinomatosis.
Introduction
We report the case of a 60-year-old female with lymphangitic carcinomatosis with a non-small cell lung cancer primary who initially failed crizotinib and platinum-based therapy, but whom ultimately experienced a dramatic response to nivolumab. The proximity of the cancer cells to T-cells within the lymphatics may make nivolumab and other immunotherapies well suited for treatment of this disease.
Case Review
A 60-year-old female with hypothyroidism, hypertension, fibromyalgia, and a forty-pack year smoking history presented with a five-month history of progressively worsening dyspnea, a dry cough, and bilateral infiltrates on imaging. The pulmonary infiltrates were predominantly left sided and associated with marked interlobular septal thickening which persisted despite several courses of antibiotics. During this time, several radiographic studies were read as being consistent with lymphangitic carcinomatosis. Her dyspnea worsened and she developed bilateral pleural effusions, prevascular adenopathy, and a pericardial effusion. She underwent a pericardial window and diagnostic thoracentesis with cytology revealing CK-7 and TTF-1 positivity consistent with primary lung adenocarcinoma.
Based on the malignant pericardial effusion, her staging was consistent with stage IV lung adenocarcinoma and molecular testing revealed a ROS-1 mutation but no translocation in this gene ( Table 1) . The patient was started on a trial of crizotinib 250 mg twice daily, but this was discontinued after 24 days secondary to intractable nausea and vomiting. CT imaging revealed progression of lymphangitic carcinomatosis after being treated with crizotinib. The patient was then transitioned to carboplatin/pemetrexed/bevacizumab and the bevacizumab was discontinued after one cycle due to intractable nausea and vomiting. After she received four cycles of carboplatin/pemetrexed, repeat CT imaging to assess response found worsening intralobular and interlobular thickening, increased bilateral groundglass opacities, and multiple new bilateral pulmonary nodules, consistent with progression of disease.
At the time of disease progression through carboplatin/pemetrexed, her performance status was low. She was wheelchair-dependent due to severe dyspnea on minimal exertion despite home oxygen at 6L by nasal cannula. She was incapable of self-care and options discussed in clinic included hospice referral or attempting additional treatment. After discussing risks and benefits, she opted to try nivolumab 3 mg/ kg IV every two weeks. The patient began to immediately note clinical improvement with improved dyspnea on follow-up clinic visit two weeks after initiating therapy. At her second follow-up visit, she was no longer wearing supplemental oxygen. After the fourth cycle of nivolumab, repeat CT imaging showed dramatic improvement in the interlobar thickening and ground glass opacities as well as disappearance of previously noted pulmonary nodules as shown in Figure 1 . The patient was continued on maintenance treatment with nivolumab 3 mg/kg every 2 weeks. Ongoing CT imaging has shown continued improvement with almost complete resolution of her interlobar thickening ( Figures  1A-1C ). At the current time, the patient has been receiving nivolumab for over two years with near-complete radiographic response.
Discussion
Lymphangitic carcinomatosis is the permeation of malignant cells into the lymphatics to the point of obstruction, most commonly occurring within the chest. While 30% to 40% of malignancies will involve intrathoracic spread, only 6% to 8% of these cases comprise lymphangitic carcinomatosis [1] . The most common primary [1, 7] .
Our patient presented with lymphangitic carcinomatosis due to stage IV ROS-1 mutant adenocarcinoma of the lung that was initially unable to tolerate crizotinib and whose disease had failed platinumbased therapy. At the time of the patient's presentation, docetaxel had been largely considered standard second-line therapy for those with advanced nonsmall cell lung cancer (NSCLC) failing platinum-based therapy. However, Brahmer et al. had just published their phase III study comparing the novel monoclonal antibody nivolumab to docetaxel for second-line treatment of advanced squamous NSCLC. This study found that nivolumab was superior in terms of overall survival (9.2 vs. 6 months, HR 0.59, 95% CI 0.44-0.79, P<0.001), response rate (20% vs. 9%, P=0.008), and progression-free survival (3.5 vs. 2.8 months; HR 0.62, 95% CI 0.47-0.81, P<0.001) [8] . Following the start of therapy and dramatic response of our patient, another phase III study comparing nivolumab to docetaxel for second-line treatment of advanced nonsquamous NSCLC. This study also found that nivolumab was superior in terms of overall survival (12.2 vs. 9.4 months; HR, 0.73, 95% CI 0.59-0.89, P=0.002) and response rate (19% vs. 12%, P=0.02). However, median progression-free survival was greater in docetaxel than nivolumab (4.2 vs. 2.3 months), although the rate of progression free survival at one year was greater with nivolumab (19% vs. 8%) [9] . While this second phase III study confirmed benefit in patients with nonsquamous NSCLC, the differences in progression free survival between the two studies was incongruent. It is thought that this may partly be attributed to the increased efficacy of nivolumab with increasing PD-1 ligand expression seen in those with non-squamous NSCLC and not squamous NSCLC and may ultimately be indicative of the mutational burden difference between the two groups [10] .
As previously stated, the prognosis of lymphangitic carcinomatosis remains dismal owing to the advanced stage of malignancy that is a usual part of its presentation. Often associated with poor performance status, patients with lymphangitic carcinomatosis are often considered for best supportive care alone to palliate symptoms as much as possible. However, there are reports of response to treatment with chemotherapy. Kikushi et al. documented a case of survival of 14 months after treatment with cisplatin and TS-1 in a case of lymphangitic carcinomatosis with unknown primary [11] . Another report showed a positive response to high-dose etopiside and cisplatin in lymphangitic carcinomatosis with lung adenocarcinoma primary [12] . Fujiwara et al. showed an almost complete response that was sustained for 7.8 months with the EGFR-TK inhibitor geftinib in a patient with advanced lung adenocarcioma and associated lymphangitic carcinomatosis [13] . Clinically, the treatment of lymphangitic carcinomatosis is usually predicated upon standard treatment of the primary malignancy. However, to the best of our knowledge this is the first documented response of lymphangitic carcinomatosis to immunotherapy.
Nivolumab is a monoclonal IgG4 antibody that blocks programmed cell death protein 1 (PD-1) on the surface of activated T-cells. By blocking the PD-1 immune checkpoint, the T-cells remain activated and can attack tumor cells at a higher rate whenever they are in close proximity. Since they rely on these cell-cell interactions for their mechanism, checkpoint inhibitors such as nivolumab tend to have a slower time to response than traditional chemotherapies which rapidly perfuse the tumor with cytotoxic chemicals. However, increased interaction of T-cells and tumors cells may increase the speed and efficacy of checkpoint inhibitors. Several studies are examining the role of tumor-infiltrating lymphocytes in potentiating the effects of nivolumab due to this close proximity. Conversely, lymphangitic carcinomatosis is characterized by lymph-infiltrating cancer cells which theoretically should also potentiate the effects of nivolumab. When a patient presents with acute illness due to lymphangitic carcinomatosis, the time to response must be considered. Based on our experience her, rapid responses in this uncommon variant of NSCLC may be achievable with anti-PD-1 immunotherapy.
Conclusion
In the setting of patients with symptomatic lymphangitic carcinomatosis, a rapid clincal response is needed. Responses to nivolumbab often require months to manifest on imaging. However, our experience indicates that some patients with lymphangitic carcinomatosis may achieve a clinical response to nivolumab that is both rapid and durable. The biological basis for this warrant further investigation, but our case illustrates that nivolumab may provide a valuable option for the treatment of lymphangitic carcinomatosis with lung primary.
